Iguratimod

Generic Name: Iguratimod

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₄N_₂O_₆S

CAS Number: 123663-49-0

Unique Ingredient Identifier: 4IHY34Y2NV

Background: Iguratimod is under investigation in Rheumatoid Arthritis.

Indication: 用于活动性类风湿关节炎。

Clinical Trials

Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD

Phase 3

Recruiting

Conditions: cGVHD

Interventions: Drug: Iguratimod

First Posted Date: 2024-02-06

Last Posted Date: 2024-02-06

Lead Sponsor: Xuzhou Medical University

Target Recruit Count: 20

Registration Number: NCT06244628

Locations: 🇨🇳
Kailin Xu, Xuzhou, Jiangsu, China

Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis

Phase 4

Recruiting

Conditions: Rheumatoid Arthritis
Therapy

Interventions: Drug: Iguratimod

First Posted Date: 2023-11-27

Last Posted Date: 2024-03-25

Lead Sponsor: Yanfeng Hou

Target Recruit Count: 117

Registration Number: NCT06146972

Locations: 🇨🇳
Yanfeng Hou, Jinan, Shandong, China

Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis

Phase 4

Not yet recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Iguratimod combined with Tofacitinib;

First Posted Date: 2023-04-07

Last Posted Date: 2023-04-07

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 138

Registration Number: NCT05803135

Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement

Not Applicable

Recruiting

Conditions: Autoimmune Diseases

Interventions: Drug: Prednisone plus leflunomide
Drug: Diprospan plus leflunomide
Drug: Diprospan plus iguratimod

First Posted Date: 2023-03-29

Last Posted Date: 2023-03-29

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 90

Registration Number: NCT05789030

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

The Clinical Efficacy of Immunomodulators in RA Patients

Phase 4

Recruiting

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Iguratimod
Drug: Adalimumab Injection
Drug: Methotrexate
Drug: Leflunomide
Drug: Hydroxychloroquine

First Posted Date: 2022-11-23

Last Posted Date: 2022-11-29

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 400

Registration Number: NCT05626348

Locations: 🇨🇳
Qilu Hospital, Jinan, Shandong, China

Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Phase 2

Conditions: Immune Thrombocytopenia

Interventions: Drug: Iguratimod

First Posted Date: 2022-03-31

Last Posted Date: 2022-03-31

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 100

Registration Number: NCT05302024

Locations: 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Phase 2

Conditions: ITP
Immune Thrombocytopenia

Interventions: Drug: Iguratimod
Drug: Danazol

First Posted Date: 2022-03-15

Last Posted Date: 2022-05-02

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 120

Registration Number: NCT05281068

Locations: 🇨🇳
Zhuo-Yu An, Beijing, China
🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China

Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO)

Phase 2

Not yet recruiting

Conditions: Hand Osteoarthritis
Inflammatory Arthritis

Interventions: Drug: placebo
Drug: Iguratimod

First Posted Date: 2022-01-31

Last Posted Date: 2022-02-08

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 150

Registration Number: NCT05216757

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

Phase 4

Recruiting

Conditions: Primary Sjögren's Syndrome

Interventions: Drug: Iguratimod Tablets
Drug: Hydroxychloroquine Sulfate Tablets

First Posted Date: 2021-07-28

Last Posted Date: 2024-10-16

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 78

Registration Number: NCT04981145

Locations: 🇨🇳
Second affiliated hospital of zhejiang university，school of medical, Hangzhou, Zhejiang, China

The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA

Phase 4

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Tofacitinib
Drug: Iguratimod
Drug: Pred

First Posted Date: 2021-06-16

Last Posted Date: 2023-11-18

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 100

Registration Number: NCT04928066

Locations: 🇨🇳
Qilu Hospital, Jinan, Shandong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy